Trends & Analysis

#Automation / robotics #Drug safety #Pharmacovigilance

Quality overtakes cost as the priority for automating PV reporting

New research, involving 200 professionals in senior roles spanning pharmacovigilance (PV), Drug Safety and Product Safety departments, has found that quality has overtaken cost as a priority in plans for automating adverse event (AE) reporting. John Price, life sciences industry consultant and partner of Arriello, which commissioned this latest research, reports on the findings.  Although the Covid-19 pandemic has… Read More

#Editor's Choice #Exclusive Content #Intelligence #Market Reports #News #Opinion #Trends & Analysis

#Biologics #Cell and gene therapy #Cobra Biologics #DNA

Swedish government and industry to boost product partnerships 

Flerie Invest led a syndicate of investors in the $52 million acquisition of Cobra Biologics, Charles River Laboratories’ DNA and protein manufacturing subsidiary in Sweden. The new entity, NorthX Biologics, will take over and expand the facility, which is equipped to provide GMP-grade plasmid DNA and technical protein manufacture at commercial scale.   Ibrahim Baylan,… Read More

#News #Trending News #Trends & Analysis

#Clinical trials #Data

Pharma and the benefits of Real World Data 

Listen to this article on the DDW Podcast: Karen Ooms, Executive Vice President and Head of Statistics with Quanticate, argues that analysing data from real-life patients has finally come of age.  Statistical consultants have, for a long time, tried to convey to the pharmaceutical industry the merit of using real world data (RWD) to help… Read More

#Exclusive Content #Trends & Analysis

#AI #Drug development #Drug discovery #Machine learning #Therapeutics

Why we are on the cusp of a golden age of medicine 

Listen to this article on the DDW Podcast:   Panna Sharma is the President and CEO of Lantern Pharma, a clinical-stage oncology biotech using AI and genomics to innovate the rescue, revitalisation, and development of precision cancer therapeutics. Lu Rahman spoke to the man behind this biotech to find out why he… Read More

#Cancer Research #Editor's Choice #Exclusive Content #Intelligence #News #Opinion #Trends & Analysis

#Biology #Drug development #Infectious diseases #MPS technology #Novel therapeutics #Organ-on-a-chip #Toxicology

Hype or hope – microphysiological systems?

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of late-stage failures of drug candidates1. Although… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Clinical trials #Data #Drug discovery #Life sciences

Clinical trials, the pandemic and technology 

Listen to this article on the DDW Podcast: Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data  The pandemic has created manifold challenges for clinical trials, but it has also proved a transformational force. The life sciences sector has succeeded in making a… Read More

#Exclusive Content #Trends & Analysis

#AI / data analytics / healthtech / informatics #Drug discovery #Technology

Oncology is a major focus for AI drug discovery companies

The application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. The potential for AI to address these pain points has drawn significant attention from investors and players in the pharmaceutical industry.  Typically, the development… Read More

#Market Reports #News #Trends & Analysis

#Digital therapeutics #GlobalData #Pharmaceuticals #Therapeutics

Opportunities in Japan’s neurology digital therapeutics market

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions; GlobalData says several opportunities exist in the digital therapeutics market for neurological diseases in Japan.  Shionogi & Co, a partner of Akili Interactive, a prescription digital medicine company of PureTech Health, has… Read More

#News #Trends & Analysis

#Data #Drug research #Drug therapy

Early therapy gives better outcomes for ulcerative colitis patients, says data  

Galapagos presented data at the United European Gastroenterology Week (UEGW) virtual 2021 congress, which suggests patients with ulcerative colitis (UC) treated with early advanced therapy within the first 18 months post diagnosis showed less residual diarrhoea and required fewer follow-up tests than those who were treated with an advanced therapy later.  Results… Read More

#News #Trends & Analysis

#Antibodies #Bispecific therapeutics #Drug development #Drug discovery

Approaching bispecific antibody engineering

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Trends & Analysis

#Biotechnology #Collaboration #Data #Technology #Webinar

Webinar reveals how to accelerate your drug discovery program 

This free-to-watch webinar, brought to you by Certara, reviews best practices for using technology to overcome challenges in order to accelerate discovery programs.  Drug discovery research requires understanding complex chemical, biological, logistical, and computational data from a variety of data sources. A key challenge for discovery scientists is efficiently accessing the most… Read More

#Intelligence #News #Trends & Analysis

#Biopharma #Biotechnology #Collaboration #Life sciences #Technology

Why quantum computing in drug discovery needs to improve  

The Pistoia Alliance has released new results from a survey of 260 attendees from life science companies across the globe, finding that almost half classify their understanding of quantum computing (QC) technology at the beginner level (48%) only. This is followed by intermediate (29%), advanced (13%), and expert at 9%. Read More

#News #Trends & Analysis

#Biopharmaceuticals #Covid-19 #GlobalData

Covid-19 shapes Indian pharma deals landscape

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only slightly… Read More

#Covid-19 #News #Trends & Analysis

#Covid-19 #GlobalData #Immunology / Virology & Vaccines #mRNA

Too many US adults unvaccinated to vaccinate children 

Following the news that Pfizer/BioNTech will apply for authorisation of their Covid-19 vaccine Comirnaty for children ages 5–11 after showing positive initial data from a trial at a lower dose in this age group; Philipp Rosenbaum, Senior Healthcare Analyst at GlobalData, offers his view.   He said: “It will be… Read More

#Covid-19 #News #Trends & Analysis

#AI #AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Pharma #Technology

Exclusive interview: BenevolentAI on the future of AI

In what BenevolentAI considers a move that deepens its drug discovery and development expertise on its board, Dr John Orloff has been appointed as a Non-Executive Director. Dr Orloff joins the BenevolentAI board as it advances plans to scale its AI platform, partnerships and drug portfolio. DDW’s Megan Thomas speaks with Dr Orloff about his… Read More

#Editor's Choice #Exclusive Content #News #Opinion #Trends & Analysis